Evidence map›Paper›PMID 28953614›Full record

ArticleMedicine2017

Chronic hepatitis E virus infection in a cirrhotic patient: A case report.

Hugo Barragué, Bertrand Condat, Nicolas Petitdidier, Eric Champagne, Christophe Renou, Jacques Izopet, Florence Abravanel

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Present and future management of viral hepatitis.World journal of gastroenterology · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Hugo BarraguéCentre de Physiopathologie de Toulouse Purpan, INSERM U1043/CNRS UMR5282/Université Toulouse III Paul-Sabatier, Toulouse Hôpital Sainte Camille, Bry sur Marne Division of Hepatology, Centre Hospitalier de Hyères, Hyères Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, Laboratoire de virologie, Centre National de Référence Hépatite E, Institut fédératif de biologie de Purpan, Toulouse, France.
Bertrand Condat
Nicolas Petitdidier
Eric Champagne
Christophe Renou
Jacques Izopet
Florence Abravanel
Hôpital Saint- Camille · FRUniversité Toulouse III - Paul Sabatier · FRCentre de Physiopathologie de Toulouse-Purpan · FRHydrogen Fuel Cells and Electro-Mobility in European Regions · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleAcute hepatitis E virus (HEV) infections are usually self-limiting in immunocompetent patients. HEV persistence has been described only in immunosuppressed patients such as solid-organ transplant recipients, patients with hematological diseases, or patients with human immunodeficiency virus (HIV) infection. PATIENT CONCERNS: A 61-year-old patient was admitted in hospital for jaundice and asthenia. DIAGNOSES: The patient had underlying cirrhosis and developed a chronic HEV infection.

interventionRibavirin therapy was initiated. OUTCOMES: Ribavirin therapy for 12 months allowed the clearance of the virus and HEV viral load remained undetectable thereafter. This patient had taken no immunosuppressive drugs, was not suffering from any autoimmune disease and was not infected with HIV. We studied the patient's anti-HEV immune response months after the viral clearance. His peripheral blood mononuclear cells (PBMC) were stimulated in vitro by HEV peptides. The patient had a mild T lymphopenia, but polyclonal stimulation of PBMC showed a robust T cell response. The response of his anti-HEV specific interferon-γ producing T cells was low. LESSONS: Other studies are now needed to identify the population with a chronic evolution of HEV infection despite no apparent immunodepression.

Indexed as

Antiviral AgentsEnzyme-Linked Immunospot AssayHepatitis, ChronicHepatitis EHumansInterferon-gammaLiver CirrhosisMaleMiddle AgedRibavirinAntiviral AgentsInterferon-gammaRibavirin

Identifiers

PMID28953614
PMCPMC5626257
OpenAlexW2757734199

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.